N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507489-20-00

Enrollment

249

Registered

2024-06-28

Start date

2024-12-10

Completion date

Unknown

Last updated

2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High cardiovascular risk (previous cardiovascular disease or familial hypercholesterolemia), Statin-intolerance

Brief summary

(self-reported) statin use 12 months after inclusion.

Interventions

DRUGRosuvastatin tablet 10mg Apotheek A15

DRUGPlacebo of rosuvastatin 10mg (tablet) as produced by Apotheek A15

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
(self-reported) statin use 12 months after inclusion.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 27, 2026